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Background: Visceral adipose tissue-derived serine proteinase inhibitor (vaspin) is an adipokine identified in
genetically obese rats that correlates with insulin resistance and obesity in humans. Recently, we found that 7% of
the Japanese population with the minor allele sequence (A) of rs77060950 exhibit higher levels of serum vaspin. We
therefore evaluated the serum vaspin levels in Japanese chronic hemodialysis patients.
Methods: Healthy Japanese control volunteers (control; n = 95, 49.9±6.91 years) and Japanese patients undergoing
hemodialysis therapy (HD; n = 138, 51.4±10.5 years) were enrolled in this study, and serum samples were subjected
to the human vaspin RIA system.
Results: The measurement of the serum vaspin levels demonstrated that a fraction of control subjects (n = 5) and
HD patients (n = 11) exhibited much higher levels (> 10 ng/ml; VaspinHigh group), while the rest of the population
exhibited lower levels (< 3 ng/ml; VaspinLow group). By comparing the patients in the VaspinLow group, the serum
vaspin levels were found to be significantly higher in the control subjects (0.87±0.24 ng/ml) than in the HD patients
(0.32±0.15 ng/ml) (p < 0.0001). In the stepwise regression analyses, the serum creatinine and triglyceride levels were
found to be independently and significantly associated with the vaspin concentrations in all subjects.
Conclusions: The creatinine levels are negatively correlated with the serum vaspin levels and were significantly
reduced in the Japanese HD patients in the VaspinLow group.
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Visceral adipose tissue-derived serine proteinase inhibi-
tor (vaspin) was identified in the visceral adipose tissue
of OLETF (Otsuka Long-Evans Tokushima Fatty) rats,
which are used in an animal model of obesity and type 2
diabetes [1]. The mRNA expression of vaspin increases
at the peak of obesity and insulin resistance in OLETF
rats. The injection of recombinant human vaspin into
diet-induced obese mice ameliorates insulin resistance
and may be a compensatory factor in the status of obes-
ity [2]. In obese adults [3-6] and children [6,7], the
serum vaspin levels increase according to the degree of
obesity and insulin resistance and decrease in association
with weight reduction brought about by life-style* Correspondence: junwada@md.okayama-u.ac.jp
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reproduction in any medium, provided the ormodifications or bypass surgery. The serum vaspin levels
in the patients with type 2 diabetes have been demon-
strated to be higher [8,9] or similar to [10] those
observed in subjects with normal glucose tolerance.
Since short-term continuous subcutaneous insulin infu-
sion decreases the plasma vaspin levels associated with
improvements in insulin sensitivity [11], the serum vas-
pin levels may be influenced by both therapeutic modal-
ities and the status of intrinsic insulin secretion in
patients with type 2 diabetes.
Some reports have evaluated the vaspin levels in
patients with vascular complications. Low vaspin serum
concentrations have been found to be correlated with re-
cently experienced ischemic events in patients with ca-
rotid stenosis [12]. The presence of microvascular
complications is also associated with low vaspin levels
[13]. Among patients receiving chronic dialysis therapy,
Seeger et al. reported that the mean serum vaspintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chronic hemodialysis (HD) patients and control subjects,
although the vaspin concentrations are positively asso-
ciated with the serum creatinine levels in HD patients
[14]. Recently, we found that 7% of the Japanese popula-
tion with the minor allele sequence (A) of rs77060950
exhibit higher levels of serum vaspin (10 ng/ml) [15] and
that several SNPs within the vaspin gene are significantly
associated with the serum vaspin concentrations, reach-
ing P-values of up to 10-35 in European populations [16].
Only a small amount of information is available
regarding the vaspin levels in HD patients. Serum vaspin
levels should be increased in HD patients due to the fact
that its small protein size, 50 kDa, which would be freely
filtered by the kidneys. Furthermore, vaspin seems to in-
crease with increasing insulin resistance and expanding
fat mass. Therefore, it was interesting to know whether
serum vaspin levels are elevated or reduced in uremic
patients undergoing dialysis, who are frequently in the
status of malnutrition. We conducted a cross-sectional
clinical study to evaluate whether the serum vaspin
levels are altered by the renal function and whether the
frequency of much higher levels of serum vaspin is dif-
ferent in HD patients. The ELISA system with a meas-
urement range up to 1 ng/ml (Adipogen) was used in
the above mentioned clinical studies. In this study, we
employed the RIA system with a wider measurement
range from 0.04 ng/ml to 60 ng/ml (Millipore, Linco
Research). We measured the serum vaspin levels in
healthy Japanese control subjects with a normal renal
function and HD patients and compared various clinical
parameters.
Methods
Patients
Healthy Japanese control subjects (n = 95, 49.9±6.91 years)
and patients undergoing hemodialysis therapy (n = 138,
51.4±10.5 years) were enrolled in this study. The healthy
control subjects received annual medical health checkups
for common disease screening at the Okayama Southern
Institute of Health. The control subjects were without any
history of medications for diabetes, hypertension and/or
dyslipidemia. The patients were receiving chronic
hemodialysis therapy (HD) at Shigei Medical Research
Hospital, Okayama, Japan. The exclusion criteria were
as follows: malignancies, active infectious diseases,
hospitalization during the previous 3 months, and ini-
tiation of hemodialysis therapy within 6 months. The
patients underwent regular hemodialysis three times a
week for 4 to 5 hours per session using polysulfone
membranes with a bicarbonate-buffered dialysate. The
blood flow was maintained in the range of 150-
200 ml/min with a dialysate flow of 500 ml/min. The
study protocol was approved by the ethics committeeof Okayama Southern Institute of Health, Okayama
University Hospital and Shigei Medical Research
Hospital, and written informed consent was obtained
from all participants.
Biochemical assays and other measurements
Body mass index (BMI) was calculated as the weight in
kilograms divided by the square of the height in meters.
Waist circumference was measured midway between the
lower rib margin and the iliac crest. Blood samples were
obtained immediately prior to starting a dialysis session.
Laboratory data, including the serum levels of creatinine,
plasma glucose, total cholesterol, high-density lipopro-
tein (HDL) cholesterol, triglycerides (TG), albumin and
hemoglobin were measured using an automatic analyzer
(Hitachi 7150; Hitachi, Tokyo, Japan). Blood pressure
(BP) was measured in the supine position before each
dialysis session.
The RIA system, which utilizes 125I-labeled vaspin as a
tracer and a rabbit polyclonal antibody raised against
purified rhvaspin, was used to measure the human vas-
pin levels in sera (Millipore, Linco Research, St. Charles,
MO, USA). Hundred μl of each standard or each sample
was pipetted in duplicate into tubes and mixed with
100 μl of human vaspin antibodies. After incubation for
22-24 hours at 4°C, 100 μl of 125I-Vaspin tracer was
added to all tubes. After incubation for another 22-
24 hours at 4°C, 10 μl of rabbit carrier and 1.0 ml of cold
(4°C) precipitating reagent were added and incubated for
20 minutes at 4°C. After centrifugation for 20 minutes at
4°C at 2000-3000 x g, the supernatant was decanted and
the radioactivity of the pellets was counted. Working ali-
quots of human vaspin standards measuring between
0.01 ng/ml and 60 ng/ml were prepared by performing
serial 1:2 dilutions of the stock standard of 60 ng/ml.
The log values of the standards were plotted versus the
sample-bound counts/total binding counts (B/B0) to
construct a standard curve to determine the concentra-
tions of serum vaspin in the unknown samples. The
linearity of the standard curve was ascertained to be
between 0.26 ng/ml and 60 ng/ml. The intra- and inter-
assay coefficients of variation (CV) were 5.5% and 12.3%
at 4.37 ng/ml and 2.7% and 12.4% at 8.44 ng/ml human
vaspin concentrations, respectively. The spike recovery
and linearity were in a range of 95.3-101.4% and 100.0-
116.2%, respectively.
Statistical methods
The descriptive data are presented as the mean ± SD.
The statistical analyses were performed by a Windows
personal computer with statistics software JMP 7 (SAS
Institute Inc., Cary, NC, USA). P-values of <0.05 or
<0.01 were considered to be statistically significant. Dif-
ferences between two groups were assessed by using the
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levels and clinical characteristics were evaluated with the
Spearman’s rank correlation test. Stepwise regression
analyses based on backward elimination were performed
to test the influence of various factors on the vaspin
serum concentrations.
Results
The serum vaspin levels in the control and HD patients
Measurement of the vaspin levels in the human serum
samples revealed that the majority of subjects displayed
vaspin levels between 0.042 and 1.57 ng/ml. A minor frac-
tion of subjects (n = 5 in the control group and n = 11 in
the HD group) displayed much higher levels, ranging from
16 to 46 ng/ml. Therefore, we classified the participants
into two subgroups based on the vaspin serum levels: Vas-
pinLow: vaspin levels < 3 ng/ml and VaspinHigh: vaspin levels
> 10 ng/ml. Henceforth, all of the statistical analyses in the
present study were performed among subgroup VaspinLow,
unless otherwise indicated (Table 1). The serum vaspin
levels were 0.54±0.33 ng/ml (range: 0.042-1.57 ng/ml) in
the total samples and were significantly higher in the con-
trol subjects (0.87±0.24 ng/ml) than in the HD patients
(0.32±0.15 ng/ml) (p < 0.0001). The serum vaspin levels
remained lower in the HD patients than in the control
subjects following adjustment for the hemoglobin levels
(0.32±0.15 ng/ml v.s. 0.92±0.32 ng/ml, p < 0.0001) and
BMI (0.32±0.15 ng/ml v.s. 0.85±0.22 ng/ml, p < 0.0001).
In the HD patients, there were no significant differ-
ences in the serum vaspin concentrations between
females (0.35±0.13 ng/ml) and males (0.30±0.16 ng/ml)Table 1 Baseline characteristics of the healthy controls with l
serum vaspin levels (control/VaspinHigh) and the chronic hem
(HD/VaspinLow) or higher serum vaspin levels (HD/VaspinHigh)
Control/VaspinLow HD/VaspinLow
Total number 90 127
Vaspin (ng/ml) 0.87 ± 0.24 0.32 ± 0.15
Gender (female: male) 48:42 41:86
Age (years) 49.7 ± 6.90 51.9 ± 10.1
BMI (kg/m2) 23.5 ± 3.84 22.0 ± 3.46
Waist circumference (cm) 78.1 ± 11.5 77.8 ± 9.69
Systolic BP (mmHg) 124 ± 16 132 ± 24
Creatinine (mg/dl) 0.73 ± 0.15 13.2 ± 2.91
Blood glucose (mg/dl) 98.6 ± 28.0 119.2 ± 43.8
Total cholesterol (mg/dl) 214.4 ± 36.0 162.2 ± 40.1
HDL cholesterol (mg/dl) 66.4 ± 15.1 45.9 ± 13.9
TG (mg/dl) 135.0 ± 86.1 127.2 ± 93.1
Albumin (g/dl) 4.58 ± 0.24 3.85 ± 0.32
Hemoglobin (g/dl) 14.0 ± 1.64 10.3 ± 0.89
The data are presented as the number, ratio or mean ± s.d. *, p < 0.05.
Vaspin Visceral adipose-tissue derived serpin, BMI Body mass index, SFA Subcutaneo
lipoprotein, TG Triglycerides.as well as between diabetic (0.30±0.11 ng/ml) and non-
diabetic (0.32±0.16 ng/ml) patients. Similarly, in the con-
trol subjects, the circulating vaspin levels were
not significantly different in the gender groups (females:
0.89±0.21 vs. males: 0.85±0.27 ng/ml).Univariate correlations
In the analysis of the total participants, including the
control and HD patients, the serum vaspin levels
were found to be statistically correlated with BMI and
the levels of plasma glucose, total cholesterol, HDL-
cholesterol, triglycerides, albumin and hemoglobin. In the
control group, the vaspin levels were significantly corre-
lated with the triglyceride levels. However, the serum
levels of vaspin did not show any statistical correlations
with any of the parameters in the HD patients (Table 2).Multivariate correlations
Multiple regression analyses were performed to test
whether any of the following factors influence the serum
vaspin concentrations: the creatinine and triglyceride
levels. When correcting for these variables using step-
wise regression analyses, the levels of creatinine and tri-
glycerides were found to be independently and
significantly associated with the vaspin concentrations in
all subjects (Table 3). The levels of triglycerides signifi-
cantly predicted the serum vaspin levels in the control
group. In the HD patients, no significant correlations
were detected between the vaspin levels and any
parameter.ower serum vaspin levels (control/VaspinLow) or higher
odialysis (HD) patients with lower serum vaspin levels
P values Control/VaspinHigh HD/VaspinHigh P values
5 11
<0.0001* 23.4 ± 6.26 31.0 ± 9.15 0.0785
0.0019* 4:1 5:6 0.0023*
0.0575 52.8 ± 5,47 45.4 ± 13.7 0.1788
0.0115* 22.6 ± 1.62 24.3 ± 4.79 0.3948
0.8701 74.2 ± 7.32 78.5 ± 9.91 0.3596
0.0049* 135 ± 16 128 ± 27 0.5561
<0.0001* 0.74 ± 0.21 13.0 ± 3.00 <0.0001*
<0.0001* 87.6 ± 9.48 115.0 ± 33.0 0.0250*
<0.0001* 211.2 ± 17.0 166.9 ± 37.8 0.0080*
<0.0001* 65.4 ± 14.8 52.0 ± 16.7 0.1467
0.5397 85.2 ± 24.4 97.2 ± 27.9 0.4147
<0.0001* 4.56 ± 0.15 3.65 ± 0.35 <0.0001*
<0.0001* 12.4 ± 2.78 10.1 ± 0.69 0.1361
us fat area, VFA Visceral fat area, BP Blood pressure, HDL High-density
Table 2 Univariate analyses of the healthy controls (n = 90), chronic dialysis patients (HD; n = 127) and all subjects,
including both the healthy controls and chronic dialysis patients (n = 217), with lower serum vaspin levels (VaspinLow)
using the circulating vaspin levels as dependent variables
Control/VaspinLow HD/VaspinLow All subjects
r P values r P values r P values
Age 0.0331 0.7663 -0.0827 0.3556 -0.1046 0.1309
BMI 0.1184 0.2866 0.0191 0.8638 0.2182 0.0047*
Waist circumference 0.0810 0.4667 0.0209 0.8154 0.0563 0.4171
Creatinine -0.0192 0.8630 0.1526 0.0881 -0.7464 <0.0001*
Blood glucose 0.1772 0.1090 -0.0218 0.8096 -0.1764 0.0108*
Total cholesterol 0.1697 0.1250 0.0987 0.2962 0.5282 <0.0001*
HDL cholesterol -0.1901 0.0852 0.0043 0.9634 0.4107 <0.0001*
TG 0.3430 0.0015* 0.1212 0.1991 0.1838 0.0097*
Albumin -0.0149 0.8934 0.0741 0.4117 0.6462 <0.0001*
Hemoglobin 0.0066 0.9526 0.0352 0.6944 0.6784 <0.0001*
*, p < 0.05. Vaspin Visceral adipose-tissue derived serpin, BMI Body mass index, HDL High-density lipoprotein, TG Triglycerides.
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Obesity has undoubtedly influenced the growth of end-
stage renal disease (ESRD) worldwide [17]; however,
some studies have suggested that higher BMIs are asso-
ciated with improved survival in patients with ESRD
[18,19]. Adipokines derived from adipose tissues regulate
energy homeostasis, insulin sensitivity, lipid metabolism,
coagulation, fibrinolysis, inflammation and vascular
functions [20]. Therefore, measuring the levels of adipo-
kines in patients with ESRD may be beneficial for pre-
dicting cardiovascular events and patient survival. In
patients with chronic kidney disease (CKD), the levels of
adipokines appear to increase in association with declines
in the glomerular filtration rate (GFR). This is most likely
due to reduced renal metabolism of adipokines, whichTable 3 Multivariate linear regression analyses of the healthy
healthy controls and chronic hemodialysis patients (n = 217),
circulating vaspin levels as dependent variables
Models Independent variables β Standardiz
1 All subjects
Age -0.003 0.002
BMI 0.001 0.005
Hemoglobin 0.012 0.014
TG 0.001 0.000
Albumin 0.148 0.070
Creatinine -0.030 0.005
Blood glucose 0.000 0.001
2 Control
Age -0.001 0.004
BMI -0.001 0.007
TG 0.001 0.000
*, p < 0.05. Vaspin Visceral adipose-tissue derived serpin, BMI Body mass index, TG tmay increase vascular risks in patients with a reduced
renal function [20]. Among the adipokines, leptin and
adiponectin are well-established vasoactive substances,
and the serum levels of both leptin and adiponectin have
been investigated in patients with ESRD. In patients with
incidental coronary heart disease (CHD), the leptin levels
exhibit a moderate association with incident CHD [21].
In dialysis patients, poor appetite is associated with fat
mass loss and declining leptin levels [22]. Similarly,
Scholze et al. demonstrated that low leptin levels predict
poor outcomes in dialysis patients, which most likely
reflects the detrimental effects of protein energy wasting
and loss of fat mass on outcomes in this population [23].
Regarding adiponectin, earlier reports have suggested that
higher adiponectin levels are linked to better outcomescontrols (n = 90) and all subjects, including both the
with lower serum vaspin levels (VaspinLow) using the
ed β βSE t value P value Model r2
-0.070 -1.247 0.214 0.586
0.006 0.104 0.917
0.077 .829 0.409
.0154 2.643 0.009*
0.063 0.692 0.490
-0.620 -6.511 0.000*
-0.030 -0.511 0.610
-0.035 -0.311 0.757 0.119
-0.010 -0.084 0.933
0.353 -3.016 0.003*
riglycerides.
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[26,27]. Drechsler et al. reported that increased longitu-
dinal levels of adiponectin are associated with higher risks
of adverse cardiovascular outcomes and death and that
this association is weakened by the confounding effects of
increased levels of N-terminal prohormone brain natri-
uretic peptide (NT-pro-BNP)[26]. These studies suggest
that the adipokines levels in patients with ESRD are influ-
enced by the renal function, nutritional state and status of
inflammation and may affect the vascular function and
clinical outcomes.
In the current study, a fraction of the Japanese popula-
tion, including both healthy subjects and HD patients,
exhibited 10-fold higher levels of serum vaspin of more
than 10 ng/ml, as demonstrated using the human vaspin
RIA system with wider concentration ranges of measure-
ment. Repeated measurement of the serum vaspin levels
in this population (VaspinHigh) always demonstrated
similarly high levels of vaspin, and one of the subjects’
parents also exhibited similar levels. Therefore, such
higher vaspin levels are primarily defined by genetic fac-
tors. Indeed, we demonstrated that a significant subpo-
pulation (7%) of both the subjects with normal fasting
glucose levels (n = 259) and patients with type 2 diabetes
(n = 275) displayed much higher levels (10-40 ng/ml;
VaspinHigh group), while the serum vaspin levels of
93% of the samples varied from 0.2 to 3 ng/ml in
the VaspinLow group. According to genotyping,
rs77060950 is tightly linked to the serum vaspin levels,
i.e. CC (0.6±0.4 ng/ml), CA (18.4±9.6 ng/ml) and AA (30.5
±5.1 ng/ml) (p < 2 ×10-16)[15]. In the current study, we
demonstrated that a similar frequency in the VaspinHigh
group was observed among the HD patients, who seemed
to be genetically defined. Furthermore, the population
with vaspin levels higher than 10 ng/ml included different
ethnic groups, i.e. ~1% in European populations, as noted
in previous reports [14]. We also demonstrated that ~1%
of the Danish twin population exhibit vaspin levels higher
than 10 ng/ml using the human vaspin RIA system [28].
By separating the patients in the VaspinHigh and VaspinLow
groups, we clearly demonstrated that the serum vaspin
levels were significantly reduced in the HD patients in the
VaspinLow group. Seeger et al. did not demonstrate differ-
ences in the mean serum vaspin concentrations between
chronic hemodialysis (HD) patients and controls, which
may be due to the fact that their analysis combined both
VaspinHigh and VaspinLow groups together. Since the
serum vaspin levels correlate with BMI, another explan-
ation for the lower vaspin levels observed in Japanese HD
patients may be related to the fact that lower BMI levels
are observed in Japanese HD patients than in German HD
patients [14].
Lower serum vaspin levels in HD patients are a uni-
que feature, since most adipokines, including leptin,adiponectin and resistin, are higher in ESRD and HD
patients. Since the molecular mass of vaspin is ~50 kDa
[1], vaspin may not be efficiently eliminated by hemo-
dialysis. The presence of lower serum vaspin levels in
HD patients suggest the existence of extra renal elimin-
ation of vaspin from the circulation, including the func-
tion of clearance receptors on the cell surface of various
cells and tissues. Since the serum vaspin levels are well-
correlated with BMI and the levels of albumin and
hemoglobin, vaspin may reflect the nutritional status of
HD patients. Recently, the circadian rhythm of the
serum vaspin levels has been reported [29]. The serum
vaspin levels are highest in the early morning before
breakfast and fall to the trough levels within two hours
after breakfast. The serum vaspin levels also exhibit pre-
prandial rises and postprandial falls at lunch and dinner,
although to lesser degrees than that observed at break-
fast [30]. In addition, central and peripheral vaspin ad-
ministration acutely reduces food intake and exerts
sustained blood glucose-lowering effects in mice [30],
suggesting the possible role of vaspin in appetite control.
The relationship between the reduced vaspin levels
observed in HD patients and appetite loss was not deter-
mined in the current study, and future studies are
required to demonstrate a such link. Since vaspin may
exert insulin-sensitizing effects and exhibit anti-
inflammatory properties in the obesity state [1,2],
reduced vaspin levels in HD patients may be linked to
adverse cardiovascular events. The current study is a
cross-sectional clinical study and has some limitations.
Cohort studies are required to demonstrate whether lower
serum vaspin levels are related to poor outcomes in HD
patients. To demonstrate such relationships in a cohort
study, genetically defined VaspinHigh and VaspinLow
groups should be analyzed separately and the VaspinHigh
group should be excluded from using vaspin as a marker.
Separation of the VaspinHigh and VaspinLow groups is also
important for comparing different ethnic groups, and fu-
ture studies are required to demonstrate whether the
current findings can also be applied to other ethnic
populations.
Conclusion
In summary, measuring the serum vaspin levels demon-
strated that ~7% of both healthy controls and HD patients
exhibit much higher levels (> 10 ng/ml; VaspinHigh group),
while the rest of the population exhibits lower levels
(< 3 ng/ml; VaspinLow group). By comparing the pa-
tients in the VaspinLow group, the serum vaspin levels
were found to be significantly higher in the control
subjects (0.87±0.24 ng/ml) than in the HD patients
(0.32±0.15 ng/ml) (p < 0.0001). In the stepwise regression
analyses, the levels of creatinine and triglycerides were
found to be independently and significantly associated
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ies are required to determine whether vaspin is a marker
of eating behavior and nutrition in HD patients and to
demonstrate the importance of the vaspin levels for pre-
dicting the outcomes of HD patients.
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